KR20230002371A - SARS-CoV-2 감염증 치료 방법 - Google Patents

SARS-CoV-2 감염증 치료 방법 Download PDF

Info

Publication number
KR20230002371A
KR20230002371A KR1020227034976A KR20227034976A KR20230002371A KR 20230002371 A KR20230002371 A KR 20230002371A KR 1020227034976 A KR1020227034976 A KR 1020227034976A KR 20227034976 A KR20227034976 A KR 20227034976A KR 20230002371 A KR20230002371 A KR 20230002371A
Authority
KR
South Korea
Prior art keywords
dantrolene
administering
subject
pharmaceutically acceptable
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227034976A
Other languages
English (en)
Korean (ko)
Inventor
아드리안 헤프너
Original Assignee
이글 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이글 파마슈티컬즈 인코포레이티드 filed Critical 이글 파마슈티컬즈 인코포레이티드
Publication of KR20230002371A publication Critical patent/KR20230002371A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227034976A 2020-04-10 2021-04-08 SARS-CoV-2 감염증 치료 방법 Pending KR20230002371A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008486P 2020-04-10 2020-04-10
US63/008,486 2020-04-10
US202063062599P 2020-08-07 2020-08-07
US63/062,599 2020-08-07
PCT/US2021/026302 WO2021207443A1 (en) 2020-04-10 2021-04-08 Methods of treating sars-cov-2 infections

Publications (1)

Publication Number Publication Date
KR20230002371A true KR20230002371A (ko) 2023-01-05

Family

ID=75787221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034976A Pending KR20230002371A (ko) 2020-04-10 2021-04-08 SARS-CoV-2 감염증 치료 방법

Country Status (12)

Country Link
US (1) US12605364B2 (https=)
EP (1) EP4132518B1 (https=)
JP (1) JP2023521163A (https=)
KR (1) KR20230002371A (https=)
CN (1) CN115361947A (https=)
AU (1) AU2021253866A1 (https=)
BR (1) BR112022020193A2 (https=)
CA (1) CA3174710A1 (https=)
IL (1) IL296517A (https=)
MX (1) MX2022012705A (https=)
WO (1) WO2021207443A1 (https=)
ZA (1) ZA202210474B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201417A (en) * 2017-10-20 2024-02-21 Eagle Res Labs Limited Dantrolene prodrugs and methods of their use
US11123328B2 (en) 2017-11-14 2021-09-21 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US12246028B2 (en) * 2018-11-27 2025-03-11 Eagle Research Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
AU2021254415A1 (en) * 2020-04-10 2022-10-20 Eagle Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome

Also Published As

Publication number Publication date
CN115361947A (zh) 2022-11-18
US20230144719A1 (en) 2023-05-11
ZA202210474B (en) 2025-12-17
MX2022012705A (es) 2022-11-07
WO2021207443A1 (en) 2021-10-14
AU2021253866A1 (en) 2022-10-20
JP2023521163A (ja) 2023-05-23
EP4132518A1 (en) 2023-02-15
IL296517A (en) 2022-11-01
US12605364B2 (en) 2026-04-21
EP4132518C0 (en) 2025-08-13
CA3174710A1 (en) 2021-10-14
BR112022020193A2 (pt) 2022-11-22
EP4132518B1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
Li et al. Therapeutic strategies for critically ill patients with COVID-19
Van Brummelen et al. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19–a formulator’s perspective
ES2810303T3 (es) Compuestos de tiazolida para tratar infecciones virales
WO2021155777A1 (zh) 药物组合物在预防和治疗新型冠状病毒肺炎中的应用
Mancuso et al. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza
EP4132518B1 (en) Dantrolene for use in methods of treating sars-cov-2 infections
US12582633B2 (en) Methods of treating severe acute respiratory syndrome
US20230181509A1 (en) The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease
WO2021188787A1 (en) Method for treatment of coronavirus infection
HK40083259A (en) Dantrolene for use in methods of treating sars-cov-2 infections
HK40083259B (en) Dantrolene for use in methods of treating sars-cov-2 infections
US20230143775A1 (en) Methods of treating coronavirus infections
US20230149364A1 (en) Methods of treating viral infections
HK40090314A (zh) 治疗严重急性呼吸综合征的方法
RU2794315C1 (ru) Способ профилактики или лечения коронавирусной и других острых респираторных вирусных инфекций
KR20220009314A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물
JP2025527908A (ja) 気道感染症を処置するための医薬乾燥粉末組成物および方法
KR20210129613A (ko) 사스 코로나바이러스 감염증 치료용 약학 조성물 및 이의 의약 용도
IT202300022647A1 (it) Uso di elysivir per il trattamento della malattia da coronavirus 2019 (covid-19)
TW202102224A (zh) 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感
Aoki Peramivir

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902